Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Commentary|Videos|May 5, 2024
Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy
Author(s)Alexander Kutikov, MD, FACS
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Alexander Kutikov, MD, FACS, chair and professor, Department of Urology and the Roberta R. Scheller Chair in Urologic Oncology at Fox Chase Cancer Center, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Advertisement
Related to this article
Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.
Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.
An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.
The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.
Perioperative nivolumab plus neoadjuvant chemotherapy did not significantly improve pCR rate or event-free survival in MIBC.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
2
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
3
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
4
Atirmociclib Plus Fulvestrant Improves PFS in HR+/HER2– Advanced Breast Cancer
5